Monday, August 12, 2013

Biosensors : Missed a beat in 1Q (CIMB)

Biosensors
Current S$0.98
Target S$1.32
Missed a beat in 1Q

 The inventory adjustment was a ‘short-term pain’s trategy by BIG to strengthen its market leadership position in its key Chinese market.1QFY14 results may trigger an investor stampede to exit but valuations will become more palatable, as its long-term game plan is still intact.

1QFY14 core net profit of US$12m (-63% yoy) missed our and consensus estimates, forming 14% of our FY14 forecast. We cut our FY14-16 EPS estimates by 14-32% for lower sales assumptions and shave off 20% of our SOP-based target price. Our Outperform rating is retained as we expect 2Q-4Q to improve. The positive financial effects of the new product, better operations and M&A accretion catalysts are understated.


Disappointing 1Q
Although we predicted that FY14 consensus estimates would be adjusted downwards, the 1QFY14 results still surprised us. The miss was primarily attributed to the revenue decline of 11% yoy from: 1) a 7% drop in IVP sales (inventory drawdown in China), and 2) a 33% decline in licensing revenue due to competition in Japan, 3) higher operating expenditure for sales and marketing efforts, and 4) the effects of the higher funding costs for the MTN programme.

2Q-4Q to play catch-up
BIG’s voluntary inventory drawdown in its China sales channels in light of the imminent ASP price cut aims to create higher volume growth in the next few quarters. Management still guided for a 15% increase in FY14 revenue, fuelled by continued double-digit product revenue growth in the EMEA and APAC regions. Specifically, it expects 2Q-4Q DES sales in China to improve significantly following the inventory adjustment. However, we do not think that licencing and royalty income will improve much in 2Q-4Q.

Outperform retained
Despite the 1QFY14 results underperformance, we still believe that BIG’s distinctively cheaper valuation and mid-term earnings outlook remain intact, which augur well for the group. We expect the initial sales/earnings uplift from the commercialisation of new products in FY15. The addition of Spectrum Dynamics will also boost earnings.



Source/Extract/Excerpts/来源/转贴/摘录: CIMB-Research,
Publish date: 12/08/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock